• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A Review and an Update on Pharmacological Treatment of Children With Attention-Deficit/Hyperactivity Disorder.注意缺陷多动障碍儿童药物治疗的综述与更新
J Korean Acad Child Adolesc Psychiatry. 2025 Jan 1;36(1):11-17. doi: 10.5765/jkacap.240040.
2
Can behavioral sensory processing problems guide us to a better pharmacological management of children with attention deficit hyperactivity disorder?: a case report.行为感觉处理问题能否引导我们更好地对注意力缺陷多动障碍儿童进行药物治疗？：一例病例报告。
Psychiatry (Edgmont). 2009 Dec;6(12):40-3.
3
The efficacy of weighted blankets for sleep in children with attention-deficit/hyperactivity disorder-A randomized controlled crossover trial.加权毯对注意缺陷多动障碍儿童睡眠的疗效：一项随机对照交叉试验。
J Sleep Res. 2024 Apr;33(2):e13990. doi: 10.1111/jsr.13990. Epub 2023 Jul 15.
4
Attention deficit hyperactivity disorder in adults: what the non-specialist needs to know.成人注意力缺陷多动障碍：非专科医生需要了解的内容。
Br J Hosp Med (Lond). 2020 Mar 2;81(3):1-11. doi: 10.12968/hmed.2019.0188. Epub 2020 Mar 16.
5
Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Neurocognitive Functions and Clinical Outcomes of Attention-Deficit/Hyperactivity Disorder in Pharmacological and Cognitive Training Interventions.神经认知结局能否辅助基于测量的注意缺陷多动障碍儿童的治疗？药物治疗和认知训练干预对注意缺陷多动障碍患者神经认知功能变化与临床结局的关系的系统评价和荟萃分析。
J Child Adolesc Psychopharmacol. 2022 Jun;32(5):250-277. doi: 10.1089/cap.2022.0028.
6
Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013-2020).新型非兴奋剂类药物时代注意缺陷多动障碍药物使用模式：澳大利亚儿童和成人的基于人群研究（2013-2020 年）。
Aust N Z J Psychiatry. 2023 May;57(5):675-685. doi: 10.1177/00048674221114782. Epub 2022 Aug 23.
7
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.从业者综述：自闭症谱系障碍儿童和青少年注意缺陷/多动障碍症状的药物治疗：系统评价和荟萃分析。
J Child Psychol Psychiatry. 2021 Jun;62(6):680-700. doi: 10.1111/jcpp.13305. Epub 2020 Aug 26.
8
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.英国心理药理学协会关于注意缺陷多动障碍药物治疗推荐的循证指南更新：推荐意见概要。
J Psychopharmacol. 2014 Mar;28(3):179-203. doi: 10.1177/0269881113519509. Epub 2014 Feb 12.
9
The quality of life of adults with attention deficit hyperactivity disorder: a systematic review.成人注意力缺陷多动障碍患者的生活质量：一项系统评价。
Innov Clin Neurosci. 2012 May;9(5-6):10-21.
10
The pooled prevalence of attention-deficit/hyperactivity disorder among children and adolescents in Ethiopia: A systematic review and meta-analysis.埃塞俄比亚儿童和青少年注意缺陷多动障碍的患病率：系统评价和荟萃分析。
PLoS One. 2024 Jul 18;19(7):e0307173. doi: 10.1371/journal.pone.0307173. eCollection 2024.

引用本文的文献

1
Emerging Breakthroughs in Pediatric Attention-Deficit/Hyperactivity Disorder Treatment.小儿注意力缺陷/多动障碍治疗的新突破
J Korean Acad Child Adolesc Psychiatry. 2025 Jan 1;36(1):1. doi: 10.5765/jkacap.240044.

本文引用的文献

1
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder.维洛沙嗪缓释胶囊（Qelbree）治疗儿童和青少年注意缺陷多动障碍的四项随机临床试验的事后分析：同伴关系和社交活动的反应。
Brain Behav. 2023 Apr;13(4):e2910. doi: 10.1002/brb3.2910. Epub 2023 Feb 27.
2
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.采用 ADHD 症状早期变化预测维拉佐酮缓释剂治疗成人 ADHD 的疗效：一项 3 期临床试验的机器学习事后分析。
Psychiatry Res. 2022 Dec;318:114922. doi: 10.1016/j.psychres.2022.114922. Epub 2022 Oct 23.
3
Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder.Serdexmethylphenidate/Dexmethylphenidate 的剂量比例性和稳态药代动力学，一种治疗注意缺陷/多动障碍的新型前药组合。
J Child Adolesc Psychopharmacol. 2022 Jun;32(5):288-295. doi: 10.1089/cap.2022.0015. Epub 2022 Jun 3.
4
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.Centanafadine 缓释片治疗成人注意缺陷多动障碍的疗效、安全性和耐受性：2 项 3 期、随机、双盲、多中心、安慰剂对照临床试验的结果。
J Clin Psychopharmacol. 2022;42(5):429-439. doi: 10.1097/JCP.0000000000001575. Epub 2022 Jun 2.
5
First Amphetamine Transdermal Patch Approved for ADHD.首款用于治疗注意力缺陷多动障碍（ADHD）的安非他明透皮贴剂获批。
JAMA. 2022 May 3;327(17):1642. doi: 10.1001/jama.2022.5727.
6
Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study.右苯丙胺透皮贴剂治疗儿童和青少年注意缺陷多动障碍的疗效和安全性：一项关键的 2 期研究结果。
J Child Adolesc Psychopharmacol. 2022 Mar;32(2):89-97. doi: 10.1089/cap.2021.0107. Epub 2022 Jan 11.
7
A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.一项关于司来吉兰右旋苯丙胺胶囊和右苯丙胺胶囊治疗注意缺陷多动障碍儿童的随机、对照实验室教室研究。
J Child Adolesc Psychopharmacol. 2021 Nov;31(9):597-609. doi: 10.1089/cap.2021.0077. Epub 2021 Oct 29.
8
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.一项关于维拉佐酮缓释胶囊对注意缺陷/多动障碍儿童和青少年学习和学校问题影响的事后分析。
Eur Child Adolesc Psychiatry. 2023 Mar;32(3):491-499. doi: 10.1007/s00787-021-01877-5. Epub 2021 Sep 28.
9
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.维洛沙嗪缓释胶囊治疗注意缺陷多动障碍儿童和青少年的执行功能结局：四项随机临床试验的事后分析。
Paediatr Drugs. 2021 Nov;23(6):583-589. doi: 10.1007/s40272-021-00470-2. Epub 2021 Sep 15.
10
Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.儿童注意缺陷多动障碍患者维拉佐酮缓释胶囊的群体药代动力学。
J Clin Pharmacol. 2021 Dec;61(12):1626-1637. doi: 10.1002/jcph.1940. Epub 2021 Aug 8.

A Review and an Update on Pharmacological Treatment of Children With Attention-Deficit/Hyperactivity Disorder.

作者信息

Lee Taeyeop, Kim Hyo-Won

机构信息

Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

J Korean Acad Child Adolesc Psychiatry. 2025 Jan 1;36(1):11-17. doi: 10.5765/jkacap.240040.

DOI:10.5765/jkacap.240040
PMID:39811027
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11725655/
Abstract
摘要